Neuren Pharmaceuticals: From New Zealand roots to ASX stardom

Neuren Pharmaceuticals: From New Zealand roots to ASX stardom
Neuren's Melbourne-based CEO Jon Pilcher credits the pharmaceutical firm's breakthrough medications to NZ research. (Image: Neuren Pharmaceuticals)
Rebecca Stevenson
It was the best-performing stock on the ASX in 2023, has a market cap of about $2.2 billion, doesn’t have an office, and was founded in New Zealand. Neuren Pharmaceutical’s medication trofinetide became the first US Food and Drug Administration (FDA) approved treatment for the disabling neurological disorder Rett syndrome in March 2023. Rett syndrome is rare, “profoundly debilitating”, and mostly affects female children. It leads to developmental delays and sometimes regressions as the child ages. Neuren s...

More Markets

NZ stocks end lower while Eroad tanks
Markets Market Close

NZ stocks end lower while Eroad tanks

The S&P/NZX 50 Index dropped 99.89 points or 0.75% to 13,289.21.

Jamie Gray 17 Oct 2025
Macpac NZ profits drop 71% as softer sales hit margins
Retail

Macpac NZ profits drop 71% as softer sales hit margins

The sales drop in New Zealand was larger than Kathmandu's.

Gregor Thompson 17 Oct 2025
Eroad shares slump 23% as it shifts focus from North America
Markets

Eroad shares slump 23% as it shifts focus from North America

Eroad cuts North America exposure, impairing $150m in assets.

Rebecca Howard 17 Oct 2025
$55m deal secures Santana mining land
Primary Sector

$55m deal secures Santana mining land

The gold miner now owns all the land where its best mining prospects lie.  

Pattrick Smellie 17 Oct 2025